Compare VOC & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VOC | XLO |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.6M | 49.0M |
| IPO Year | N/A | 2021 |
| Metric | VOC | XLO |
|---|---|---|
| Price | $3.30 | $8.51 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | ★ 106.7K | 28.3K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 12.46% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,766,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $168.77 |
| P/E Ratio | $6.00 | ★ N/A |
| Revenue Growth | N/A | ★ 589.88 |
| 52 Week Low | $2.60 | $0.46 |
| 52 Week High | $3.84 | $9.25 |
| Indicator | VOC | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 43.75 | 65.18 |
| Support Level | $3.24 | $0.62 |
| Resistance Level | $3.31 | $9.22 |
| Average True Range (ATR) | 0.15 | 0.45 |
| MACD | -0.01 | -0.22 |
| Stochastic Oscillator | 35.42 | 74.77 |
VOC Energy Trust is a statutory trust. It is created to acquire and hold a term net profits interest for the benefit of the Trust unitholders. The underlying properties include VOC Brazos' net interests which are located in the states of Kansas and Texas. The trust is entitled to receive the net proceeds from the sale of production of oil and natural gas attributable to the underlying properties. The business and affairs of the Trust are managed by the Trustee, and neither VOC Brazos nor any of its affiliates has the ability to manage or influence the operations of the Trust.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.